Related Experiment Videos

Disseminated granuloma annulare: efficacy of cyclosporine therapy

S Spadino1, A Altomare, C Cainelli

  • 1Institute of Dermatology, University of Milan, IRCCS Galeazzi Orthopedic Institute, Via Galeazzi 4, 20161 Milan, Italy.

International Journal of Immunopathology and Pharmacology
|July 13, 2006
PubMed

Insights

Systemic cyclosporine therapy effectively treated disseminated granuloma annulare in four patients, achieving complete resolution within three weeks. This immunosuppressive drug was well-tolerated, showing no relapses during follow-up.

Area of Science:

  • Dermatology
  • Immunology

Background:

  • Granuloma annulare is a common dermatological condition.
  • Disseminated granuloma annulare presents a therapeutic challenge.

Observation:

  • Four patients with disseminated granuloma annulare were treated.
  • Treatment involved a six-week cycle of cyclosporine therapy.
  • Dosing started at 4 mg/kg/day, tapering every two weeks.

Findings:

  • Complete or significant clinical resolution occurred within three weeks for all patients.
  • No relapses were observed during tapering or the subsequent 12 months.
  • Cyclosporine was well-tolerated with no therapy-related side effects.

Implications:

  • Systemic cyclosporine is a viable treatment option for disseminated granuloma annulare.
  • Treatment may require careful patient monitoring in a hospital setting.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...